Related Experiment Video
Updated: Feb 28, 2026

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
Published on: December 16, 2021
Molecular mechanisms and therapies for tumor inhibition through the arginine metabolism pathway
Yuhang Xu1, Mingxin Yu1, Yi Zhang1
1Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Abstract:
Tumors are one of the major diseases leading to human death. Arginine metabolism plays an important role in tumor occurrence and metastasis. Based on the levels of arginine in tumor cells, methods such as recombinant arginine deiminase are used to reduce arginine in order to inhibit tumor growth. However, arginine deprivation therapy has limited efficacy in tumor cells due to increased arginine synthesis, resistance to chemotherapeutic agents, metabolic reprogramming, and the suppression of immune cells in the tumor microenvironment. Meanwhile, with the revelation of many new molecular mechanisms by which arginine controls tumor cell growth, numerous newly designed molecules targeting arginine metabolic pathways for cancer treatment have emerged. In this review, we integrate and analyze the responses of tumor cells and immune cells such as T cells to arginine and strategies for cancer therapy. At the molecular level, we review and discuss the mechanisms of specifically blocking arginine-regulated metabolic reprogramming in cancer cells, the effector factors from pathogenic microorganisms and metabolites from plants in inhibiting cancer cells via arginine metabolism, and arginine tRNA metabolic pathway. Finally, we discuss the mechanisms and case studies of using antineoplastic agents that target arginine metabolic pathways in combination. This review collects and integrates the mechanisms and experiences of treating various cancers through arginine and its metabolic derivatives, providing direct therapy guidance for cancer patients with disordered arginine metabolism in the tumor and immune cells.
Insights
Arginine metabolism is crucial in cancer. While arginine deprivation therapy shows promise, tumor cells develop resistance. New strategies targeting arginine pathways offer improved cancer treatment options.
Area of Science:
- Oncology
- Metabolic pathways
- Immunology
Background:
- Arginine metabolism is integral to tumor development and metastasis.
- Current arginine deprivation therapies face limitations due to tumor resistance mechanisms.
- Emerging molecular insights reveal arginine's role in cancer cell proliferation.
Purpose of the Study:
- To review arginine's impact on tumor and immune cells.
- To analyze novel therapeutic strategies targeting arginine metabolism.
- To integrate current knowledge for improved cancer treatment guidance.
Main Methods:
- Literature review and analysis of molecular mechanisms.
- Examination of arginine's role in cancer cell and immune cell responses.
- Discussion of combination therapies targeting arginine pathways.
Main Results:
- Arginine metabolism reprogramming and immune suppression hinder therapy efficacy.
- Novel molecular targets and therapeutic agents are emerging.
- Combination strategies show potential for enhanced anti-cancer effects.
Conclusions:
- Understanding arginine metabolism is key to overcoming therapeutic resistance.
- Targeting arginine pathways, including tRNA metabolism, offers new treatment avenues.
- Integrated approaches combining arginine-targeting agents provide clinical guidance for cancer patients.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor Immunotherapy

